Core Viewpoint - The announcement by Fuhong Hanlin (02696) regarding the inclusion of Fuzhuoning (Apatinib) in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List (2025) is a significant development for the company and the treatment of specific breast cancer patients [1] Group 1 - Fuzhuoning has been included in the Class B category of the National Medical Insurance Drug List for 2025, specifically for use in HR-positive, HER2-negative recurrent or metastatic breast cancer patients who have progressed after endocrine therapy [1] - The new National Medical Insurance Drug List will be officially implemented on January 1, 2026 [1] - Fuzhuoning is an innovative CDK4/6 small molecule inhibitor that was approved for marketing in China in May 2025 [1] Group 2 - The initial approved indication for Fuzhuoning is in combination with Fulvestrant for HR-positive, HER2-negative recurrent or metastatic breast cancer patients who have previously received endocrine therapy [1] - In September 2025, Fuzhuoning received an additional indication for use in HR-positive, HER2-negative locally advanced or metastatic breast cancer adult patients, in combination with aromatase inhibitors as initial endocrine therapy [1]
复宏汉霖：复妥宁 (枸橼酸伏维西利胶囊)获纳入国家医保药品目录